Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | G6PD | P11413 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 10/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873113 | 0.96 | MAPT (0.53) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL526836 | 0.87 | ALDH1A1 (0.47) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL6209994 | 0.87 | MAPT (0.43) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL16787410 | 0.87 | KAT6A (0.46) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL387290 | 0.87 | MAPT (0.47) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL11484961 | 0.85 | MAPT (0.46) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL26028856 | 0.84 | MAPT (0.42) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL16115191 | 0.82 | KAT6A (0.41) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL25753316 | 0.82 | KAT6A (0.41) | MAPTNOTUMGRM5KDM4EALDH1A1 | |
| SCHEMBL254441 | 0.82 | TP53 (0.49) | MAPTNOTUMGRM5KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359308-B2 | Pyrazine kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-8877760-B2 | Substituted pyrazine-2-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | ALEXION PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013078466-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131040-A1 | PYRAZINE KINASE INHIBITORS | SYK, ZAP70, LCK | MAPT 3092/4885NOTUM 2946/4885GRM5 2129/4885 |
| US-20140309209-A1 | Pyrazine Kinase Inhibitors | SYK, ZAP70, LCK | MAPT 3092/4885NOTUM 2946/4885GRM5 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.